Sangamo Biosciences Positions for Growth with Strategic Shareholder Decisions Sangamo Biosciences (SGMO) just unveiled an update. At Sangamo Therapeutics’ Annual Meeting on June 4, 2024, stockholders approved several key prop…
Nektar, Verastem among healthcare additions in Russell Microcap; Assertio, Sangamo removed In its annual 2024 Russell index reconstitution, about 213 companies will be added and 198 deleted from the Russell Microcap Index.The following notable…
Sangamo Biosciences: Navigating Biopharma Risks Beyond the Minefield Sangamo Biosciences (SGMO) has disclosed a new risk, in the Manufacturing category. Sangamo Biosciences, as a biopharmaceutical company, does not e…
SGMO Stock Earnings: Sangamo Therapeutics Misses EPS, Misses Revenue for Q1 2024 Sangamo Therapeutics (NASDAQ: SGMO ) just reported results for the first quarter of 2024. Sangamo Therapeutics reported earnings per share of -27 cents. This was below the analyst estimate for EPS of -21 cents. The company reported revenue of $481,000. This was 92.77% worse than the analyst estimate for revenue of $6.65 million. InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at editor@investorplace.com. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. Legendary Investor Predicts: “Forget A.I.
Sangamo Therapeutics, Inc. (SGMO) Q1 2024 Earnings Call Transcript Sangamo Therapeutics, Inc. (NASDAQ:SGMO ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Louise Wilkie - Vice President, Investor Relations and Corporate Communications Sandy Macrae - Chief Executive Officer Amy Pooler - Head of Research Nathalie Dubois-Stringfellow - Chief Development Officer Conference Call Participants James Stamos - Jefferies Gena Wang - Barclays Luis Santos - H.C. Wainwright Ritu Baral - TD Cowen Bill Chappell - Truist Operator Good day, and welcome to the Sangamo Therapeutics First Quarter 2024 Teleconference Call.
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Lags Revenue Estimates Sangamo Therapeutics (SGMO) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to earnings of $0.12 per share a year ago.
Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast.
Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted 20 Sangamo abstracts for presentation at the 27th ASGCT Annual Meeting being held May 7-11, 2024, in-person in Baltimore, MD and in a virtual format. Presentations will focus on the progression of Sangamo’s neurology-focused pre-clinical Jetzt den vollständigen Artikel lesen
Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics to Present Neurology Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at ASGCT.